TM Owner Day One Biopharmaceuticals
Ojemda Suspension IV 10mg/mL Oral Suspension
Global Shipping : Reliable Global Distribution Network
Express Delivery : Priority Shipping for Every Order
Secure Payments : Trusted Payment Protection System
Disclaimer
Secure Handling
24/7 Worldwide Support
Global Access
Worldwide Access to Health
Cold-Chain Expert
Excellence in Cold-Chain
Trusted Supply
Certified Medical Supply
Indications & Clinical Uses
- This catalogue entry, 'Ojemda Suspension IV', appears to be a data error: tovorafenib (Ojemda) is approved only as an oral tablet and an oral suspension for reconstitution - no intravenous (IV) formulation of tovorafenib exists from any regulator, and the sheet's own Form field confirms this is an oral suspension, not an injectable.
- The content below therefore describes the real, approved Ojemda oral suspension so the underlying molecule information is accurate, but this specific brand/strength combination should be treated as unconfirmed until the catalogue entry is corrected or removed.
- Ojemda oral suspension contains tovorafenib, a type II RAF/MEK-pathway kinase inhibitor, indicated in the United States for patients 6 months of age and older with relapsed or refractory pediatric-type low-grade glioma (LGG) harbouring a BRAF fusion or rearrangement, or BRAF V600 mutation, and is prescribed only by a paediatric oncology or neuro-oncology specialist.
Side Effects
- Assuming this entry refers to the genuine Ojemda oral suspension, common side effects include hair colour changes (about three-quarters of patients), rash, fatigue, viral infection, vomiting, headache, bleeding, fever, dry skin, constipation, nausea, acne-like skin reactions, and upper respiratory infection, each affecting 30% or more of patients.
- There is no boxed warning on the label.
- More serious effects include hepatotoxicity, with raised liver enzymes in up to three-quarters of patients (occasionally severe), photosensitivity skin reactions in around 1 in 8 patients, and bleeding events in over 40% of patients, which can occasionally be serious.
- Report yellowing of the skin or eyes, unusual bruising or bleeding, or a severe sunburn-like reaction promptly.
- There is no intravenous form of tovorafenib, so none of the infusion-related reactions sometimes seen with IV cancer therapies apply to this molecule.
Precautions & Warnings
- There is no intravenous formulation of tovorafenib approved anywhere; if a vial or injectable product labelled this way is encountered, it should not be administered and the prescription should be verified with the prescriber and pharmacy before use.
- For the genuine oral suspension, liver function should be checked before starting and monitored regularly because of hepatotoxicity risk, and growth should be assessed periodically in children, since treatment-related growth effects have been reported.
- Sun protection is essential because of photosensitivity risk.
- Ojemda may harm a developing baby; effective non-hormonal contraception should be used during treatment and for 28 days (females) or 2 weeks (males) after the last dose, and breastfeeding should be avoided during treatment and for 2 weeks afterward.
- The suspension must be measured only with the dosing syringe supplied and used immediately after reconstitution.
Avoid Interactions
- For the genuine oral tovorafenib product, strong or moderate CYP2C8 inhibitors and inducers should be avoided, as they can raise or lower tovorafenib levels.
- Tovorafenib induces CYP3A enzymes and can make CYP3A-metabolised medicines, including hormonal contraceptives, less effective; a non-hormonal contraceptive method should be used instead.
- Tell the treating specialist about every prescription medicine, over-the-counter medicine, herbal product, and supplement being used.
- Because no IV tovorafenib product exists, there are no compatibility or infusion-site interaction data to report for an intravenous form; any product presented as 'Ojemda IV' should be treated with suspicion and confirmed against the official Day One Biopharmaceuticals or Ipsen Pharma prescribing information before use.
References
Frequently Asked Questions
No. Tovorafenib (Ojemda) is approved only as an oral tablet and an oral suspension; no intravenous formulation exists from the FDA, EMA, or any other regulator. A catalogue listing named 'Ojemda Suspension IV' is a labelling error, not a real product.
Ojemda oral suspension (tovorafenib) treats relapsed or refractory low-grade glioma, a childhood brain tumor, in patients 6 months and older whose tumor has a BRAF fusion, rearrangement, or V600 mutation. It is taken by mouth, never injected.
Common side effects include hair color changes, rash, fatigue, vomiting, headache, bleeding, and fever, each affecting around a third or more of patients. Serious effects include raised liver enzymes and sun-sensitivity skin reactions, so regular liver tests are needed.
Avoid strong CYP2C8 inhibitors or inducers, since they change tovorafenib blood levels. Tovorafenib also makes hormonal contraceptives less effective, so a non-hormonal method should be used. Avoid unprotected sun exposure because of the risk of photosensitivity skin reactions.
Do not accept or administer it. No intravenous tovorafenib product is approved anywhere, so this label indicates an error. Confirm the prescription and product with the pharmacist or prescriber, and check it against the official oral tablet or oral suspension packaging.
Yes, the genuine oral suspension is approved from 6 months of age for the specific brain tumor indication. Doctors monitor growth and liver function regularly during treatment, since tovorafenib can affect both in children.
Trusted & Reliable – Your Partner in Global Distribution.
We provide comprehensive lines of pharmaceutical products to support all your healthcare distribution needs.
